Chordia Therapeutics Posts 1.45 Billion Yen Parent Recurring Loss
Chordia Therapeutics reported a parent recurring loss of 1.45 billion yen for 2025/26, versus a loss of 1.77 billion yen.
Chordia Therapeutics reported a parent recurring loss of 1.45 billion yen for 2025/26, versus a loss of 1.77 billion yen.